• Participants have access to resources, technology and expertise (including a staff of 19) for early, first steps in the drug discovery process
• Awarded a scope of work with all expenses paid
• Opportunity to learn from other scientists, venture investors, and pharma and biotech veterans who have led large teams to develop new medicines in industry
• An early look at projects that have initial seed investment dollars and that have been matured and de-risked by a team of skilled drug developers
• View of early-stage opportunities with an ability to specify the data needed to assess the opportunity’s value
• With Yale and UConn receiving 93% of NIH-funded research in CT, a window into innovative research in the state
• PITCH projects have full access to the Yale Center for Molecular Discovery, staffed by a team of experienced biomedical scientists with experience in both academia and the biopharmaceutical industry.
• The Target Expression Core at UConn is staffed by a team with expertise in bacterial expression systems, large scale purification and preliminary characterization of target proteins.
PITCH received an investment of $10 million over three years from the Connecticut Bioscience Innovation Fund.
PITCH has funded 23 projects addressing unmet clinical needs in cancer, inflammation and infectious disease with levels of support exceeding $500,000 for projects since inception.